Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Welireg
Belzutifan is an orally bioavailable small molecule inhibitor of hypoxia-inducible factor-2α (HIF-2α), indicated for the treatment of Von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC), not requiring immediate surgery. HIF-2α is a transcription factor that plays a role in the development of certain types of cancer, including RCC. By inhibiting HIF-2α, belzutifan helps to reduce tumor growth and spread.
Belzutifan is used to treat Von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC) that does not require immediate surgery.
Outcome:
Decreased belzutifan levels
Mechanism:
Increased metabolism of belzutifan
Outcome:
Increased midazolam levels
Mechanism:
Inhibition of CYP3A4
Outcome:
No clinically significant interaction expected
Mechanism:
N/A
Most likely new formulation: extended-release formulation (Year: 2025, 70% confidence)
Based on clinical trial data and current usage trends, there is a 90% likelihood that belzutifan will remain approved for the treatment of VHL-associated RCC.
Antineoplastic Agent, HIF-2α Inhibitor
Pyrazole carboxamide